

Construction of *Vibrio Harveyi* Autoinducer-2  
Signalling System in *Escherichia Coli* Using  
Biobrick Methodology

Jeremy Kubik<sup>1</sup>

<sup>1</sup>Health Sciences Centre

University of Calgary, Calgary, Alberta, Canada

T2N 4N1

[jfkubik@ucalgary.ca](mailto:jfkubik@ucalgary.ca)

Abstract

Microorganisms use pheromones to monitor their own population density as well as to detect and interact with other microbial species in a process known as quorum sensing (QS). We, the University of Calgary 2009 iGEM team, have engineered the *Vibrio harveyi* AI-2 signalling system in *Escherichia coli*. This has been done by constructing the signalling circuit using the ‘Biobrick’ molecular cloning technique used in the International Genetically Engineered Machines (iGEM) competition. This circuit has been cloned into a BioBrick plasmid and verified for submission to the Registry of Standard Biological Parts. The signalling circuit was also cloned into and verified in pCS26, a plasmid that will allow the cloning of a library of  $\Delta\sigma^{70}$  promoters to control levels of LuxPQ, periplasmic proteins in the AI-2 signalling cascade. Optimal AI-2 signalling will be dependent on these levels. Further, this system will be coupled with the expression of expression of *aiiA*, a gene that codes for an AHL-degrading enzyme.

Keywords:

Autoinducer-2    Signalling    *Escherichia coli*    Biobrick    Quorum Sensing

## **Introduction**

Bacteria are able to communicate by producing and releasing chemical signal molecules termed autoinducers in a process called Quorum Sensing (QS)<sup>1</sup>. An increase in local population density of bacteria results in the accumulation of autoinducers until a minimal threshold concentration is reached, whereby bacteria are able to organize their behaviour by coordinating their gene expression. Such coordinated behaviour includes virulence induction, swarming, biofilm formation and genetic competence<sup>2</sup>.

QS was first observed in the bioluminescent bacteria *Vibrio fischeri*<sup>3</sup>, where light was emitted only at high population densities, but could be induced in low population densities with the presence of an extracellular substance, later identified as the autoinducer N-acylhomoserine<sup>4</sup> (AHL). An AHL signalling system is already present in the Registry of Biological Parts.

Further research in QS led to the discovery of the universal signalling molecule<sup>5</sup> autoinducer-2 (AI-2), which has been characterized in the gram-negative, bioluminescent marine bacterium *Vibrio harveyi*<sup>1</sup>. AI-2 binds to the periplasmic protein LuxP forming an AI-2-LuxP complex that interacts with LuxQ, a membrane bound histidine kinase<sup>6</sup>. At low population density corresponding to low AI-2 levels, LuxQ autophosphorylates and then subsequently phosphorylates the cytoplasmic protein LuxU<sup>5</sup>. LuxU then passes its phosphate to LuxO, and phospho-LuxO complexes with transcription factor  $\sigma^{54}$  to activate the transcription of the genes encoding five regulatory small RNAs (sRNAs) termed Qrr1-5<sup>7</sup> (Figure 1a). These sRNAs bind and destabilize the mRNA of *luxR*<sup>8</sup>, a transcriptional activator of the luciferase operon *luxCDABE*<sup>9</sup>. As the mRNA of *luxR* is

degraded in the presence of low levels of AI-2 and low cell density, *V. harveyi* will not express bioluminescence.

In high population densities and thus high AI-2 levels, LuxQ changes from a kinase to a phosphatase, and thus removes the phosphate of LuxU, which subsequently removes the phosphate of LuxO<sup>1</sup> (Figure 1b). Unphosphorylated LuxO does not complex with  $\sigma^{54}$ , and therefore does not produce sRNAs. This leads to unblocked *luxR* mRNA allowing its translation that drives the expression of bioluminescence via luciferase.

We have engineered the *Vibrio harveyi* AI-2 signalling system in *Escherichia coli* using the molecular cloning techniques used in the International Genetically Engineered Machines (iGEM) competition. This AI-2 signalling system will be coupled with the expression of *aiiA*, a gene that encodes an AHL-degrading enzyme partaking in quorum quenching, allowing us to target biofilm maintenance. This has been done by engineering a genetic circuit encoding the AI-2 signalling cascade (termed the signalling circuit) and a circuit containing the *qrr4* promoter followed by Registry-available inverter (BBa\_Q04510) and *aiiA* (BBa\_C0160) (collectively termed the response circuit).

The construction of the AI-2 signalling system in *E. coli* will add a second cell-to-cell communication system into the Registry of Standard Biological Parts, quite different from the AHL system already present. AHL signalling requires fewer proteins and is produced by the gene *luxI* and can freely diffuse out of the cell and into another<sup>10</sup> where it complexes with LuxR, activating transcription of the luciferase operon<sup>11</sup>. Relative to the AI-2 system, the AHL system does not use secondary messengers, and as a result, one AHL molecule cannot be amplified into multiple signals. The AI-2 system, however, allows for signal amplification due to its phosphorylation cascade. Moreover, AI-2

signalling is considered a universal signalling molecule because it is used by both gram positive and gram negative species, while AHL is merely used by gram negative species<sup>12</sup>. Thus the gram negative *E. coli* housing the AI-2 system will be able to respond to AI-2 from both gram positive and negative species.

Furthermore, the construction of the AI-2 signalling system in *E. coli* will allow for the fine tuned coordination of bacterial behaviour because any gene can be expressed by a highly dense population if it is simply cloned downstream of the signalling cascade. Just as important, the set-up of this system in the laboratory strain of *E. coli* will serve as an important and effective means to study AI-2 signalling used by pathogenic bacteria to induce virulence, and to develop drugs that may inhibit such pathogenicity by blocking QS.

This paper discusses the construction of the AI-2 *V. harveyi* signalling circuit ( $\Delta luxPQ$  followed by a terminator, tetracycline-repressible promoter, *luxOU* and a terminator) (Figure 2) in *E. coli*. Using BioBrick methodology, this circuit was constructed in a BioBrick vector and was then cloned into the pCS26 vector. The latter will allow the cloning of a library of 256 different promoters (termed  $\Delta\sigma^{70}$  promoters) in front of the  $\Delta luxPQ$  operon with the goal of optimizing AI-2 signalling by altering expressions levels of these periplasmic proteins.

## **Materials and Methods**

### BioBrick Cloning and Verification

The iGEM BioBrick (BBK) cloning technique allows for the simple and quick assembly of genetic circuits, and was employed here to construct the signalling circuit. Each genetic part is standardized with flanking endonuclease restriction sites: the BBK prefix (*EcoRI*, *NotI*, *XbaI*) and suffix (*SpeI*, *NotI*, *PstI*). Once a genetic part (gene, ribosome binding site, promoter, etc...) acquires these sites by PCR amplification and has been cloned into a BBK vector, the construction of genetic circuits (ie  $\geq 2$  genetic parts) involves the restriction digest of the “insert” and the “recipient” (Figure 3). Once cut and ligated, the *XbaI* and *SpeI* restriction sites overlap to form a “scar” in which the BBK restriction sites between the assembled parts disappear. This method also allows for cloning of one part either upstream or downstream of another part while conserving the BBK prefix and suffix that flank the assembled parts, facilitating subsequent cloning. The three methods of verifying BioBrick construction include (1) Restriction Digest, (2) PCR and (3) DNA sequencing. The assembly of the signalling circuit is depicted in Figure 4.

### Site-Directed Mutagenesis of $\Delta luxPQ$

*luxPQ* in a cosmid form was initially obtained from Bonnie Bassler, from which it was amplified using the LuxPQ-F and LuxPQ-R primers (Table 1, Figure 5) and cloned into a pCR-BLUNT-II-TOPO vector (Invitrogen, CA) (Figure 6a). The QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, CA) was used to make specific non-random point mutations to remove the following BBK restriction sites from *luxPQ*: *EcoRI* (from *luxP*) and *EcoRI* and *XbaI* (from *luxQ*). This was done by synthesizing oligonucleotide primers

specific to these sites (LuxPQ-M1F, LuxPQ-M2F and LuxPQ-M3F; Table 1, Figure 7a) to introduce the silent mutations. This was then sequenced at the University of Calgary DNA Sequencing Facility (University Core DNA Services, Calgary, AB, Canada) with the LuxPQ-F and LuxPQ-S1 primers to verify the elimination of these sites.

#### *Cloning of $\Delta luxPQ$ into BBK Vector*

$\Delta luxPQ$  was amplified from pCR-BLUNT-II-TOPO vector using LuxPQ-RS-F and LuxPQ-RS-R primers (Table 1, Figure 5) and platinum *Pfx* (*pPfx*) (Invitrogen, CA) according to the manufacturer's specifications. The cycling conditions were as follows: 94°C for 5 minutes; 36 X (94°C for 30 seconds; 62°C for 30 seconds; 68°C for 4 minutes); 68°C for 10 minutes; the reaction was held at 4°C. PCR products were run on a 0.8% Agarose gel after which the four products were pooled and purified using the QIAquick PCR Purification Kit (QIAGEN; Hilden, Germany). DNA concentration and purity were measured using the NanoDrop 1000 Spectrophotometer (NanoDrop, DE). 1  $\mu$ g of linear DNA and the psB1AC3 (Figure 6b) backbone were then both digested with *EcoRI* and *PstI* overnight at 37°C. Phosphates were removed from the vector backbone using Antarctic phosphatase (New England Biolabs, ON) for 30 minutes at 37°C, followed by enzyme inactivation at 65°C for 10 minutes. Ligation was performed with QuickLigase (New England Biolabs, ON) at room temperature for 5 minutes. The ligate was transformed into chemically-competent TOP10 cells as described by Sambrook & Russell<sup>13</sup>, and plated on Luria Bertani(LB)-chloramphenicol [35mg/L] and LB-ampicillin [100mg/L] agar plates, and incubated at 37°C overnight.

Screening was done using colony PCR with LuxPQ-F, LuxPQ-R, BBK-CP-F and BBK-CP-R primers (Table 1, Figure 5) and platinum *Taq* (*pTaq*) (Invitrogen, CA) according to the manufacturer's specification. Cycling conditions were as follows: 94°C for 6 minutes; 36 X (94°C for 30 seconds; 55°C for 45 seconds; 72°C for 4 minutes); 72°C for 10 minutes; held at 4°C. The products were then run on a 0.8% agarose gel. LB-broth with chloramphenicol [35mg/L] and ampicillin [100mg/L] were used for overnight cultures. Plasmids were isolated using the GenElute Plasmid Mini Prep kit (Sigma, MO), and DNA purity and concentration were measured using the NanoDrop 1000 Spectrophotometer (NanoDrop, DE).  $\Delta luxPQ$  in psB1AC3 was sequenced at the University of Calgary DNA Sequencing Facility using BBK-CP-F/R primers (University Core DNA Services, AB).

#### Construction of Signalling Circuit in BBK Vector

Sequencing revealed the loss of the *PstI* site on the BBK suffix, and thus a plasmid switch of  $\Delta luxPQ$  from psB1AC3 to psB1AK3 (Figure 6c) and back into psB1AC3 was performed to recover the suffix following protocols described above. The other components of the signalling circuit (terminator-Tetracycline repressible promoter-*luxOU*-terminator; BBK: B0015-R0040-*LuxOU*-B0015) were constructed in psB1AK3<sup>14</sup> and this construct was cut with *XbaI* and *PstI* and cloned downstream of *SpeI* and *PstI*-cut  $\Delta luxPQ$  (Figure 4 a-f). This was done following the protocols described above. Screening of  $\Delta luxPQ$ -B0015-R0040-*LuxOU*-B0015 (hereafter called signalling circuit) in the psB1AC3 vector was done by colony PCR using the following sets of primers: BBK-CP-F/R and LuxPQ-F, LuxOU-R. The circuit was subsequently sequenced with BBK-CP-F, BBK-CP-R and R0040-R (Table 1) primers.



*Moving Signalling Circuit into pCS26*

The signalling circuit was cloned from psB1AC3 into pCS26, a plasmid containing a Kanamycin resistance gene (Figure 6d). This was done by digesting the signalling circuit insert and pCS26 vector with NotI, and then following the protocols for ligation, transformation and verification as described above. The presence and directionality of the signalling circuit in pCS26 was verified by PCR, pairing the pCS26-S-F primer (Table 1) separately with LuxPQ-R and LuxOU-R primers. The signalling circuit in the pCS26 vector was also sequenced with pCS26-S-F and LuxOU-R primers.

## **Results**

### Verifying *luxPQ* mutation and cloning $\Delta luxPQ$ into BBK Vector

We reasoned that *E. coli* could serve as a suitable chassis to house the AI-2 signalling system; however, certain modifications to the operons found in *V. harveyi* had to be made before BBK construction in *E. coli*. *luxPQ* was obtained in a cosmid, cloned into pCR-BLUNT-II-TOPO, and silently mutated at specific nucleotides to remove BBK restriction sites with the operon. Sequencing revealed successful nucleotide base pair changes and conservation of amino acid sequence (Figure 7).  $\Delta luxPQ$  was then cloned from pCR-BLUNT-II-TOPO into the psB1AC3 vector. This was done using LuxPQ-RS-F and LuxPQ-RS-R primers to add the BBK prefix and suffix to the operon. Subsequent verification by PCR revealed the expected band size of  $\Delta luxPQ$  at around 3.9kb for each of the products (Figure 8).

These products were pooled and the concentration of linear PCR product was measured to be 316.9ng/ $\mu$ L. Linear BBK-flanked  $\Delta luxPQ$  was then cloned into psB1AC3 and transformed into TOP10 cells. Subsequent screening by colony PCR revealed a band at ~3.9kb and isolated plasmid was sequenced and found to be missing the *PstI* restriction site on the BBK suffix (results not shown).

To recover the *PstI* site, a plasmid switch of  $\Delta luxPQ$  from psB1AC3 to psB1AK3 was performed. Colonies were screened by PCR using BBK-CP-F/R primers and had desired band sizes of ~3.9kb (results not shown) once run on an agarose gel.  $\Delta luxPQ$  was then moved back into psB1AC3 to allow for the antibiotic selection while constructing the signalling circuit in psB1AK3. Similar to the first plasmid switch, a colony PCR was set up with LuxPQ-F/R and BBK-CP-F/R primers to verify the presence of  $\Delta luxPQ$  in

psB1AC3. Both sets of primers confirmed the desired band size for most of the screened colonies (Figure 9).

#### Construction of Signalling Circuit in BBK Vector

The B0015-R0040-*LuxOU*-B0015 construct was then successfully cloned downstream of  $\Delta luxPQ$  in psB1AC3 using the BBK construction technique. This was verified by colony PCR with BBK-CP-F/R and LuxPQ-F/LuxOU-R primers where one colony had the single expected band size of around 6.1 kb (Figure 10). The signalling circuit was then sequenced with BBK-CP-F, BBK-CP-R and R0040-R primers and verified the presence of desired parts in the circuit (Figure 11).

#### Moving Signalling Circuit from BBK Vector to pCS26

The signalling construct was cloned from psB1AC3 into pCS26 by *NotI* digest. This was verified by plasmid PCR by pairing the pCS26-S-F primer separately with LuxPQ-R and LuxOU-R primers to verify the presence and directionality of the circuit. Two colonies revealed expected sizes, respectively, for both sets of primers: 4.0kb and 6.1kb (Figure 12). One colony of the signalling circuit in pCS26 was then sequenced with the pCS26-S-F primer and the LuxOU-R primer, which verified the presence of  $\Delta luxPQ$  and *luxOU*, respectively (Figure 13). As the construct was cloned into pCS26 by *NotI* digest, the *EcoRI* site of the BBK prefix and the *PstI* site of the BBK suffix were no longer present.

## **Discussion**

AI-2 signalling is an effective means by which bacteria such as *V. harveyi* are able to communicate and coordinate their gene expression. Our aim was to engineer the *V. harveyi* AI-2 signalling system in *E. coli* by constructing a signalling circuit ( $\Delta luxPQ$ -B0015-R0040-*luxOU*-B0015) using BBK methodology. This circuit was cloned and verified in the BBK and pCS26 plasmids.

Although using Biobricks ensures the standardization of genetic parts and circuits to allow for further construction, we found it quite difficult to clone large pieces (>3.0 kb) using this method. A method such as TOPO cloning would potentially provide a quicker means to attempt construction, however, would not necessarily be of easy use to synthetic biologists compared to using Biobricks.

### Construction of Signalling Circuit in BBK

After numerous trials,  $\Delta luxPQ$  was cloned into a BBK vector, only to reveal the loss of the *PstI* restriction site on the BBK suffix. Cloning of  $\Delta luxPQ$  into psB1AC3 was done with *XbaI* and *PstI* and because the vector and insert were successfully ligated, the mutation in the *PstI* site must have been spontaneous and have occurred after ligation, yet before sequencing.

The B0015-R0040-*LuxOU*-B0015 construct was subsequently cloned downstream of  $\Delta luxPQ$  (Figure 4). The signalling circuit was constructed in this manner because cloning  $\Delta luxPQ$  from the TOPO vector into the BBK vector took several attempts, whereas *luxOU* was cloned from TOPO into BBK on the first trial, allowing construction to continue around the latter operon.  $\Delta luxPQ$  was more difficult than *luxOU* to clone into

the BBK vector most likely because of the size difference in these constructs (3.8kb compared to 1.9kb). Similarly, several attempts were made to clone  $\Delta luxPQ$  (as the insert) upstream of B0015-R0040-*LuxOU*-B0015 in psB1AK3 because the absence of the *PstI* site would have no effect on this cloning method (Figure 3). These attempts, however, were unsuccessful as the gels run after PCR revealed wrong sized bands. This construction approach was unsuccessful again, probably because of the size difference between the constructs.

With these unsuccessful attempts, it was reasoned that the B0015-R0040-*LuxOU*-B0015 construct should be inserted downstream of  $\Delta luxPQ$ . This required the recovery of the *PstI* site on the BBK suffix of  $\Delta luxPQ$  in psB1AC3. This was done by performing a plasmid switch of  $\Delta luxPQ$  into psB1AK3. As the other part of the signalling circuit (B0015-R0040-*LuxOU*-B0015) was already present in the psB1AK3 vector,  $\Delta luxPQ$  was switched back into psB1AC3 to allow for antibiotic selection when cloning these pieces together. These two plasmid switches were successful (Figure 9) and allowed for the B0015-R0040-*LuxOU*-B0015 construct to be cloned downstream of  $\Delta luxPQ$ . This was verified to be successful by PCR (Figure 10) and sequencing (Figure 11).

No ribosome binding sites were cloned into this circuit because both the *luxPQ* and *luxOU* operons have internal ribosome binding sites. Although terminators also exist within these operons, Registry-available terminators were cloned downstream of both operons for further insulation, particularly for *luxPQ* to ensure that *luxOU* stays solely under control of the R0040 promoter.

*Importance of Signalling Circuit in pCS26*

After the signalling circuit was constructed in psB1AC3, it was then cloned into pCS26 (Figure 4). This was done by *NotI* digest and did not ensure directional cloning; therefore, PCR was done with gene specific and vector primers not only to verify the presence of certain elements within the construct, but to identify the colonies where the insert was cloned in the right direction. The direction of the signalling circuit in pCS26 was most crucial because the promoter region of  $\Delta luxPQ$  lies between the *XhoI* and *BamHI* cloning site on the vector, just upstream of the *NotI* multiple cloning site (Figure 6d). This region will allow for the cloning of a library of variable strength  $\Delta\sigma^{70}$  promoters in order to alter levels of LuxPQ. These protein levels are important because luxP and luxQ are found in the periplasm, an area of limited space in the cell, and if they are under constitutive control, the cell will most likely be overloaded. The promoters will be constructed with primers with four degenerate bases in the promoter consensus sequence allowing for 256 possible promoters. These will be separately cloned into the pCS26 vector between the *XhoI* and *BamHI* sites upstream of  $\Delta luxPQ$ . The purpose of this procedure is to identify promoters capable of optimizing AI-2 signalling by producing a certain amount of LuxPQ. This will be done by transforming a reporter circuit ( $P_{qrr4}$  followed by GFP) that will provide functional data for AI-2 signalling, whereby the brightest colony in the absence of AI-2 and the darkest colony in the presence of AI-2 will be identified. This reporter will simultaneously be used to test whether the signalling circuit is functional. It should be noted that *luxOU* is under constitutive control of the TetR (R0040) promoter because the LuxU and LuxO proteins are found in the cytoplasm, an area of considerably greater space than the periplasm.

### Signalling Circuit in Overall Goal

Although the construction of a reporter circuit will be crucial to optimize AI-2 signalling and ensure that the circuit is functional, there are many other important facets to achieving this goal. The reporter circuit itself must be functional, something that will be tested with mutant LuxO proteins that will either mimic the phosphorylated and active or unphosphorylated and inactive forms of LuxO. Moreover, once the signalling circuit is functional, we seek to couple this QS system with a desired response to demonstrate how AI-2 signalling can be used. This requires the construction of a response circuit, again tested with the mutant LuxO proteins and then coupling this circuit with the signalling circuit. This entire project is depicted in Figure 14.

### Response Circuit

The response circuit that has been envisioned and is currently under construction<sup>15</sup> comprises the *qrr4* promoter followed by the registry-available  $c1\lambda$  inverter (BBa\_Q04510) and *aiiA* (BBa\_C0160). If coupled with the signalling circuit and in the presence of AI-2 (or in high population density), the engineered *E. coli* will produce *aiiA*, an enzyme that will degrade AHL, another QS signal molecule used by bacteria. This will target biofilm maintenance as bacteria such as *Pseudomonas aeruginosa* rely on this molecule for biofilm formation<sup>16</sup>. In this sense, the AI-2 produced by the bacteria in the biofilm will serve as the input to our system, resulting in the degradation of AHL. Further, it may be useful to clone another gene downstream of the inverter called *dspB* from *Actinobacillus actinomycetemcomitans* that encodes an enzyme that can hydrolyze the polysaccharide matrix present in a biofilm and thus cause biofilm detachment<sup>17</sup>.

*Significance of AI-2 Signalling System in E. Coli*

Once complete, the power of the AI-2 signalling system coupled with a response circuit in a laboratory strain of *E. coli* lies within the principle of QS and coordinating bacterial behaviour. The *E. coli* will be able to express a gene with a desired function at high population densities simply if this gene is cloned downstream of the inverter on the response circuit. This engineered system will prove quite versatile with respect to the output from AI-2 signalling.

The usefulness of AI-2 signalling in *E. coli* stretches far beyond the ability to clone in a gene of interest to express in high population densities. This safe, non-pathogenic, laboratory *E. coli* model of AI-2 signaling will contribute to the understanding of QS systems used by pathogenic bacteria to induce virulence. Periplasmic protein LuxP has been identified as a ribose-binding protein and its crystal structure has been determined along with important amino acids for AI-2 binding<sup>18</sup>. Although this allows for the investigation of other LuxP-binding molecules *in silico*, the presence of AI-2 signalling in *E. coli* will allow for *in vitro* investigations of activating and inactivating ligands. With this comes the development of novel therapeutics aimed at attenuating QS and thus virulence induction in pathogenic bacteria by, for example, synthesizing a drug capable of competitively inhibiting the AI-2 binding site on LuxP. Targeting and preventing QS is particularly appealing considering the emergence of increasingly antibiotic resistant bacteria<sup>19</sup>.



### **Acknowledgements**


I am most grateful and thankful for the support from the UofC iGEM 2009 team's facilitators Sonja Georgijevic, Thane Kubik, Christian Jacob and Anders Nygren. I also wish to thank the entire UofC iGEM Team 2009 for their help and support throughout this summer research project. My work was sponsored by the O'Brien Centre Summer Studentship at the UofC and the laboratory facilities were provided by the O'Brien Centre for Health Sciences.

**Tables & Figures**

<b>Primer</b>	<b>Sequence</b>	<b>GC (%)</b>	<b>Tm (°C)</b>
LuxPQ-M1F	GTGAATTAGCAACA <u>GAGTTC</u> GGAAAGTTCTTCC	42.4	75.4
LuxPQ-M2F	CGCACACACCA <u>GAGTTC</u> CGTTTTCTAACG	51.7	76.0
LuxPQ-M3F	CCTCCATTGGT <u>TCGAGA</u> CACATGCTCG	55.6	75.6
LuxPQ-S1	CCGTGATAATAACTTTGAGC	40	56
LuxPQ-RS-F	<u>GAATTCGGCCGCTTCTAGA</u> ATGCTCGATAAA AACTAAAAGAGC	33.3	64.0
LuxPQ-RS-R	<u>CTGCAGCGCCGCTACTAGT</u> CCGATACCCTAGA AAAAACAATGC	41.7	68.0
LuxPQ-F	ATGCTCGATAAAAACTAAAAGAGC	33.3	64.0
LuxPQ-R	CCGATACCCTAGAAAAACAATGC	41.7	68.0
BBK-CP-F	CACCTGACGTCTAAGAAACC	50.0	60.0
BBK-CP-R	AGGAAGCCTGCATAACGCG	57.9	60.0
R0040-R	TGCTCAGTATCTCTATCACTG	42.9	60.0
LuxOU-R	CCCATTTCAAATCTCCTCATG	42.9	60.0
pCS26-S-F	AGCTGGCAATTCCGACGTC	57.9	60.0


**Table 1. List of primers used in the construction of the signalling circuit.** Primer name, sequence, GC content and melting temperature are all listed here. Primers LuxPQ-M1F, LuxPQ-M2F and LuxPQ-M3F were designed to incorporate a mutation in the *luxPQ* sequence to eliminate the any BBK sites (shown in pink). The single nucleotide change is underlined. The green nucleotides for LuxPQ-RS-F and LuxPQ-RS-R represent the BBK restriction sites to be incorporated to flank *luxPQ*. Primers designed by Thane Kubik.

Jeremy Kubik




**Figure 1. AI-2 signalling cascade in the absence and presence of AI-2.** (a) In the absence of AI-2, LuxQ autophosphorylates and subsequently phosphorylates the cytoplasmic protein LuxU, which passes its phosphate to LuxO. Phospho-LuxO complexes with transcription factor  $\sigma^{54}$  to activate the transcription of genes downstream of one of the five *qrr4* promoters. The promoter depicted here is *qrr4*, as it is the one engineered into our system. (b) In the presence of AI-2, LuxQ changes from a kinase to a phosphatase, and thus removes the phosphate of LuxU, which subsequently removes the phosphate of LuxO. Nothing binds to the *qrr4* promoter and therefore there is no expression of downstream genes.

Jeremy Kubik




**Figure 2. Schematic depiction of AI-2 signalling circuit.** This genetic circuit encodes the proteins necessary for the AI-2 signalling cascade (see Figure 1). Curved arrows represent promoters, while straight arrows represent genes. The *luxOU* operon is under constitutive control of the TetR promoter (BBa\_R0040), whereas the  $\Delta luxPQ$  operon is under control of the  $\Delta\sigma^{70}$  promoter, allowing for control of expression levels. For simplicity, the terminators after each operon are not shown in this circuit.

Jeremy Kubik




**Figure 3. Schematic diagram of BioBrick construction technique created by Sonja Georgijevic.** The cloning of a genetic part (donor component #1) in front of another part (recipient component #1) requires digesting with *EcoRI/SpeI* and *EcoRI/XbaI* respectively. Ligation results in the formation of a ‘scar’ in which the *XbaI* and *SpeI* restriction sites between the two parts overlap, removing any restriction site present. Similarly, the insertion of a genetic part (donor component #2) behind another part (recipient component #2) requires digesting with *XbaI/PstI* and *SpeI/PstI* respectively. The BBK construction method allows for conservation of the BBK prefix and suffix that flank the entire circuit to allow for subsequent cloning, while ensuring no restriction sites are present between each part. Diagram adapted from Idempotent Vector Design for Standard Assembly of Biobricks (Tom Knight).

Jeremy Kubik



**Figure 4. Schematic Diagram of Signalling Circuit Construction.**  $\Delta luxPQ$  in TOPO vector after mutagenesis (a) was BBK amplified into the psB1AC3 vector (b), acquiring BBK restriction sites. Similarly, *luxOU* was moved from TOPO (c) into the psB1AC3 vector (d). The B0015-R0040-*luxOU*-B0015 circuit in psB1AK3 was constructed from *luxOU* in psB1AC3 (e). This construct was then cloned downstream of  $\Delta luxPQ$  (f), and the entire construct was then moved into the pCS26 vector (g), which will allow for the cloning of the library of synthetic  $\sigma^{70}$  promoters. (*LuxPQ* =  $\Delta luxPQ$ ; *LuxOU* = *luxOU*; TOPO = TOPO vector; AC = psB1AC3; AK = psB1AK3; TetR = Tetracycline repressible promoter (BBa\_R0040); red octagon = terminator (BBa\_B0015);  $\Delta\sigma^{70}$  =  $\sigma^{70}$  promoter region).


Jeremy Kubik



**Figure 5. Schematic diagram of annealing regions for primers used with *luxPQ*.**

Primers are represented by black arrows: (1) LuxPQ-F, (2) LuxPQ-R, (3) LuxPQ-RS-F, (4) LuxPQ-RS-R, (5) BBK-CP-F, (6) BBK-CP-R. Green lines shown attached to primers 3 and 4 represent the BBK prefix and suffix. Primers 1-4 specifically anneal to *luxPQ*, whereas primers 5 and 6 anneal to the BBK vector backbone (*psB1AC3* or *psB1AK3*).

Jeremy Kubik



**Figure 6. TOPO, BioBrick and pCS26 plasmids.** (a) The multiple cloning site is located directly upstream of *lacZα* in the pCR-BLUNY II-TOPO vector (Invitrogen, CA). Genes coding for Zeocin and Kanamycin resistance are also present on this vector with the pUC origin of replication. (b) The salient features of psB1AC3 include ampicillin and chloramphenicol resistance, high copy number and the BBK prefix and suffix for housing genetic BBK parts. Although not depicted, Registry part BBa\_P1010 (cell death gene) is initially present within the multiple cloning site to allow for selection after cloning a desired part into the vector. The origin of replication is pMB1 – high copy. (c) The



psB1AK3 (also with Registry insert BBa\_P1010) vector is similar to psB1AC3, although it has a gene for kanamycin resistance in place of chloramphenicol. This plasmid (d) The pCS26 vector is low copy and its multiple cloning site is flanked by *NotI* restriction sites. It also contains the *XhoI* and *BamHI* sites for cloning of the  $\Delta\sigma^{70}$  promoters, and has a gene for kanamycin resistance.

Plasmid maps adapted from invitrogen.com (a), iGEM Registry (b, c), Genomic Profiling of Iron-Responsive Genes in *Salmonella enterica* Serovar Typhimurium by High-Throughput Screening of a Random Promoter Library (Bjarnason *et al.*, 2003) (d).

Jeremy Kubik

(a)

```

Query 30  ATGAAGAAAGCGTTACTATTTTCCCTGATTCTATGGTCGGTTTTTCTCCAGCGTCTCAA 89
          |||
Sbjct 1   ATGAAGAAAGCGTTACTATTTTCCCTGATTCTATGGTCGGTTTTTCTCCAGCGTCTCAA 60

Query 90  GCAACACAAGTTTTGAATGGGTACTGGGGTTATCAAGAGTTTTTGGACGAGTTTCCCGAG 149
          |||
Sbjct 61  GCAACACAAGTTTTGAATGGGTACTGGGGTTATCAAGAGTTTTTGGACGAGTTTCCCGAG 120

Query 150 CAACGAAATCTGACCAATGCTTTATCAGAAGCAGTACGAGCACAGCCGGTCCCCTGTCT 209
          |||
Sbjct 121 CAACGAAATCTGACCAATGCTTTATCAGAAGCAGTACGAGCACAGCCGGTCCCCTGTCT 180

Query 210 AAACCGACACAACGCCCGATTAAAAATATCAGTGGTTTACCCAGGACAGCAAGTTTCAGAT 269
          |||
Sbjct 181 AAACCGACACAACGCCCGATTAAAAATATCAGTGGTTTACCCAGGACAGCAAGTTTCAGAT 240

Query 270 TACTGGGTAAGAAATATTGCATCATTCGAAAACGTTTGTATAAGTTGAATATTAAGTAC 329
          |||
Sbjct 241 TACTGGGTAAGAAATATTGCATCATTCGAAAACGTTTGTATAAGTTGAATATTAAGTAC 300

Query 330 CAACTGAACCAAGTGTCTTACTCGTCCAAATGCTGATATCAAGCAACAAAGCTTGTCTATTA 389
          |||
Sbjct 301 CAACTGAACCAAGTGTCTTACTCGTCCAAATGCTGATATCAAGCAACAAAGCTTGTCTATTA 360

Query 390 ATGGAAGCGCTCAAGAGCAAATCGGATTACTTGATTTTCACGCTTGATACGACAAGACAC 449
          |||
Sbjct 361 ATGGAAGCGCTCAAGAGCAAATCGGATTACTTGATTTTCACGCTTGATACGACAAGACAC 420

Query 450 CGTAAATTTGTTGAGCACGTTTTGGACTCAACGAACACCAAATTGATCTTGCAAAATATC 509
          |||
Sbjct 421 CGTAAATTTGTTGAGCACGTTTTGGACTCAACGAACACCAAATTGATCTTGCAAAATATC 480

Query 510 ACTACACCAGTCCGTGAGTGGGACAAACATCAACCGTTTTTATATGTCCGATTTGACCAC 569
          |||
Sbjct 481 ACTACACCAGTCCGTGAGTGGGACAAACATCAACCGTTTTTATATGTCCGATTTGACCAC 540

                                     LuxPQ-M1F
                                     ───────────────────────────────────▶
Query 570 GCAGAAGGCAGTCGTGAATTAGCAACA GAGTTC GGAAAGTTCTTCCAAAACACACATAT 629
          |||
Sbjct 541 GCAGAAGGCAGTCGTGAATTAGCAACA GAATTC GGAAAGTTCTTCCAAAACACACATAT 600

Query 630 TACAGTGTGCTCTACTTTTCTGAAGGTTATATTAGCGATGTGAGAGGTGATACTTTTATT 689
          |||
Sbjct 601 TACAGTGTGCTCTACTTTTCTGAAGGTTATATTAGCGATGTGAGAGGTGATACTTTTATT 660

Query 690 CACCAAGTAAACCGTGATAATAACTTTGAGCTACAATCAGCGTATTACACGAAGGCAACC 749
          |||
Sbjct 661 CACCAAGTAAACCGTGATAATAACTTTGAGCTACAATCAGCGTATTACACGAAGGCAACC 720

Query 750 AAGCAATCCGGCTATGATGCTGCGAAAGCGAGTTTAGCAAAACATCCAGATGTTGATTTT 809
          |||
Sbjct 721 AAGCAATCCGGCTATGATGCTGCGAAAGCGAGTTTAGCAAAACATCCAGATGTTGATTTT 780

Query 810 ATCTATGCATGTTTCGACCGACGTAGCATTAGGTGCAGTAGACGCACTGGCTGAGTTGGGA 869
          |||
Sbjct 781 ATCTATGCATGTTTCGACCGACGTAGCATTAGGTGCAGTAGACGCACTGGCTGAGTTGGGA 840

Query 870 CGTGAAGATATTATGATCAATGGCTGGGGTGGAGGCTCTGCTGAGTTAGACGCTATCCAG 929
          |||
Sbjct 841 CGTGAAGATATTATGATCAATGGCTGGGGTGGAGGCTCTGCTGAGTTAGACGCTATCCAG 900

Query 930 AAGGGTGATTTAGACATCACCGTCATGCGTATGAATGATGACACTGGCATAGCCATGGCA 989
          |||
Sbjct 901 AAGGGTGATTTAGACATCACCGTCATGCGTATGAATGATGACACTGGCATAGCCATGGCA 960

Query 990 GAAGCGATTAAGTGGGACTTGGAAAGATAAACAGTCCGACCGTATACTCAGGTGACTTT 1049
    
```

Construction of *Vibrio Harveyi* Autoinducer-2 Signalling System in *Escherichia Coli* Using Biobrick Methodology

Jeremy Kubik

```

Sbjct  961  |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 1020
          GAAGCGATTAAGTGGGACTTGGAAGATAAACAGTTCGACCGTATACTCAGGTGACTTT

Query  1050  GAAATCGTAACAAAGGCAGATTCACCGGAGAGAATCGAAGCGCTGAAAAAGCGCGCATTT 1109
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1021  GAAATCGTAACAAAGGCAGATTCACCGGAGAGAATCGAAGCGCTGAAAAAGCGCGCATTT 1080
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1110  AGATATTCAGATAATTGATGACAACAACGCGATCAAACATTA AAAAGCGTCGCTCGCTGG 1169
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1081  AGATATTCAGATAATTGATGACAACAACGCGATCAAACATTA AAAAGCGTCGCTCGCTGG 1140
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1170  CGACGCTCATAACAAAGATCATCATTTTTAGTTCTTGCCCAATTATTCTGGGGATTTTCA 1229
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1141  CGACGCTCATAACAAAGATCATCATTTTTAGTTCTTGCCCAATTATTCTGGGGATTTTCA 1200
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1230  TTCAGAGCTATTACTTCTCCAAGCAAATCATTTGGCAAGAAGTAGACCGAACCAAACAGC 1289
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1201  TTCAGAGCTATTACTTCTCCAAGCAAATCATTTGGCAAGAAGTAGACCGAACCAAACAGC 1260
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1290  AAACCTCTGCACTGATCCACAATATATTTGATAGCCACTTTGCGGCGATCCAGATACATC 1349
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1261  AAACCTCTGCACTGATCCACAATATATTTGATAGCCACTTTGCGGCGATCCAGATACATC 1320
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1350  ATGACAGTAATTCCAAGAGCGAAGTCATTCGTGATTTCTACTGATCGCGACACGGATG 1409
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1321  ATGACAGTAATTCCAAGAGCGAAGTCATTCGTGATTTCTACTGATCGCGACACGGATG 1380
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
    
```

LuxPQ-M2F

```

Query  1410  TGCTCAACTTTTTCTCTCCTCAGTATCGACCAAAGCGATCCGTCGCACACACCA GAGTTC 1469
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1381  TGCTCAACTTTTTCTCTCCTCAGTATCGACCAAAGCGATCCGTCGCACACACCA GAATTC 1440
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1470  GTTTTCTAACGGACCACAAAGGCATCATTTGGGACGATGAAATGCGCATTTCTATGGTG 1529
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1441  GTTTTCTAACGGACCACAAAGGCATCATTTGGGACGATGAAATGCGCATTTCTATGGTG 1500
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1530  TGAACGACCTTATCCTTGATAGCCTTGCCAATCGGGTCAGTTTCAGTAACAACCTGGTATT 1589
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1501  TGAACGACCTTATCCTTGATAGCCTTGCCAATCGGGTCAGTTTCAGTAACAACCTGGTATT 1560
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
    
```

LuxPQ-M3F

```

Query  1590  ACATTAATGTCATGA CCTCCATTGGTTCGAGACACATGCTCGTGCGCCGTGTCGGATCC 1649
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1561  ACATTAATGTCATGACCTCCATTGGT CTTAGACACATGCTCGTGCCGCCGTGTCGGATCC 1620
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1650  TAGACCCCTTCAACAGGAGAGGTGCTTGGTTTCTCATTTAATGCCGTCGTCTTAGACAACA 1709
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1621  TAGACCCCTTCAACAGGAGAGGTGCTTGGTTTCTCATTTAATGCCGTCGTCTTAGACAACA 1680
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1710  ACTTCGCTTTGATGAAAAAGCTCAAGAGTGAAAGTAACGTCGACAATGTGGTGCTGGTTG 1769
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1681  ACTTCGCTTTGATGAAAAAGCTCAAGAGTGAAAGTAACGTCGACAATGTGGTGCTGGTTG 1740
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1770  CTAATAGCGTTCCTTTAGCAAACCTTTGATTGGTGATGAGCCATATAACGTTGCTGATG 1829
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1741  CTAATAGCGTTCCTTTAGCAAACCTTTGATTGGTGATGAGCCATATAACGTTGCTGATG 1800
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1830  TATTGCAGCGTAAAAGTTTCAAGACAAAAGACTCGATAAGCTGTTGGTAATAGAAACGCCAA 1889
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1801  TATTGCAGCGTAAAAGTTTCAAGACAAAAGACTCGATAAGCTGTTGGTAATAGAAACGCCAA 1860
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1890  TCGTCGTAATGTCAGTGACTACCGAGCTTTGCTTGTGACGGTACAAGACAATCAGAGTG 1949
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sbjct  1861  TCGTCGTAATGTCAGTGACTACCGAGCTTTGCTTGTGACGGTACAAGACAATCAGAGTG 1920
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||

Query  1950  TGGTGACATTACAAATCCAACATATTTCTAGCCATGCTTGTCATCGATCATCGGTATGATCA 2009
          ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
    
```

Construction of *Vibrio Harveyi* Autoinducer-2 Signalling System in *Escherichia Coli* Using Biobrick Methodology

Jeremy Kubik

```
|||||
Sbjct 1921 TGGTGACATTACAAATCCAACATATTCTAGCCATGCTTGCATCGATCATCGGTATGATCA 1980
Query 2010 TGATTGCCTTAATGAGTAGGGAATGGATTGAGAGTAAAGTTTCGGCGCAGTTAGAATCTT 2069
|||||
Sbjct 1981 TGATTGCCTTAATGAGTAGGGAATGGATTGAGAGTAAAGTTTCGGCGCAGTTAGAATCTT 2040
Query 2070 TGATGTCTTACACCCGCTCTGCTCGTGAGGAAAAAGGGTTTGAACGATTTGGCGGTTCGG 2129
|||||
Sbjct 2041 TGATGTCTTACACCCGCTCTGCTCGTGAGGAAAAAGGGTTTGAACGATTTGGCGGTTCGG 2100
Query 2130 ATATTGAAGAGTTTGATCACATCGGTTCAACCCCTGAAAGTACATTCGAAGAGCTTGAAG 2189
|||||
Sbjct 2101 ATATTGAAGAGTTTGATCACATCGGTTCAACCCCTGAAAGTACATTCGAAGAGCTTGAAG 2160
Query 2190 CGCAGAAGAAGTCGTTCCGAGATCTGTTAATTTTGCTTATCACCCATCATGGTTGGT 2249
|||||
Sbjct 2161 CGCAGAAGAAGTCGTTCCGAGATCTGTTAATTTTGCTTATCACCCATCATGGTTGGT 2220
Query 2250 CTGAAGAGAGTGTCTGATTCAGATGAACCCTGCCGCGCAAAGAATTAGTGATCGAAG 2309
|||||
Sbjct 2221 CTGAAGAGAGTGTCTGATTCAGATGAACCCTGCCGCGCAAAGAATTAGTGATCGAAG 2280
Query 2310 ACGATCATGAAATCATGCATCCGGTCTTCCAAGGCTTTAAAGAGAAAATTGACCCACACC 2369
|||||
Sbjct 2281 ACGATCATGAAATCATGCATCCGGTCTTCCAAGGCTTTAAAGAGAAAATTGACCCACACC 2340
Query 2370 TCAAAATGGCGGCTCAAGGTGCGACGTTGACTGGGGTGAACGTGCCTATTGGTAATAAGA 2429
|||||
Sbjct 2341 TCAAAATGGCGGCTCAAGGTGCGACGTTGACTGGGGTGAACGTGCCTATTGGTAATAAGA 2400
Query 2430 TCTACCGATGGAACCTGTGCGCAATTCTGTTGATGGCGATATCAGTGGCATTATTGTGC 2489
|||||
Sbjct 2401 TCTACCGATGGAACCTGTGCGCAATTCTGTTGATGGCGATATCAGTGGCATTATTGTGC 2460
Query 2490 AAGGCCAAGACATTACAACACTTATCGAAGCCGAGAAGCAGAGTAACATTGCGCGTAGAG 2549
|||||
Sbjct 2461 AAGGCCAAGACATTACAACACTTATCGAAGCCGAGAAGCAGAGTAACATTGCGCGTAGAG 2520
Query 2550 AAGCAGAAAAATCGGCGCAAGCACGTCAGACTTCCCTTGCTAAAATGAGCCATGAAATTC 2609
|||||
Sbjct 2521 AAGCAGAAAAATCGGCGCAAGCACGTCAGACTTCCCTTGCTAAAATGAGCCATGAAATTC 2580
Query 2610 GTACGCCAATCAACGGCATTTTAGGTGTCGCCCAATTATGAAAGATTCTGTGATACAC 2669
|||||
Sbjct 2581 GTACGCCAATCAACGGCATTTTAGGTGTCGCCCAATTATGAAAGATTCTGTGATACAC 2640
Query 2670 AAGAGCAGAAGAATCAAATCGACGTCCTGTGCCACAGTGGCGAGCACTTCTTGCAGTAC 2729
|||||
Sbjct 2641 AAGAGCAGAAGAATCAAATCGACGTCCTGTGCCACAGTGGCGAGCACTTCTTGCAGTAC 2700
Query 2730 TGAACGATATTCTCGATTTCTCAAAGATAGAGCAGGGCAAGTTCAATATTCAGAAACACC 2789
|||||
Sbjct 2701 TGAACGATATTCTCGATTTCTCAAAGATAGAGCAGGGCAAGTTCAATATTCAGAAACACC 2760
Query 2790 CGTTCTCCTTCACCGATACCATGCGTACATTGGAAAATATTTATCGTCCGATTTGCACAA 2849
|||||
Sbjct 2761 CGTTCTCCTTCACCGATACCATGCGTACATTGGAAAATATTTATCGTCCGATTTGCACAA 2820
Query 2850 ATAAGGGGGTGGAGTTGGTCATCGAGAATGAGCTTGACCCGAATGTTGAAATCTTCACCG 2909
|||||
Sbjct 2821 ATAAGGGGGTGGAGTTGGTCATCGAGAATGAGCTTGACCCGAATGTTGAAATCTTCACCG 2880
Query 2910 ATCAAGTCCGCTTGAATCAGATTCATTTAACTTAGTGAGTAATGCCGTTAAGTTCACGC 2969
|||||
Sbjct 2881 ATCAAGTCCGCTTGAATCAGATTCATTTAACTTAGTGAGTAATGCCGTTAAGTTCACGC 2940
Query 2970 CGATTGGCTCGATTGACTGCACGCAGAACTTGAACAATTCATGGTGGGAGAACAGCG 3029
|||||
Sbjct 2941 CGATTGGCTCGATTGACTGCACGCAGAACTTGAACAATTCATGGTGGGAGAACAGCG 3000
```

Construction of *Vibrio Harveyi* Autoinducer-2 Signalling System in *Escherichia Coli* Using Biobrick Methodology

Jeremy Kubik

```

Query 3030 TGTTAGTTGTGGAAGTACTGACTGATACTGGCATCGGCATTGAAAGCGATAAGCTCGACCAA 3089
          |||
Sbjct 3001 TGTTAGTTGTGGAAGTACTGACTGATACTGGCATCGGCATTGAAAGCGATAAGCTCGACCAA 3060

Query 3090 TGTTTCGAACCTTTTGTGCAAGAAGAGTCGACAACCACACGCGAATATGGCGGTAGCGGCC 3149
          |||
Sbjct 3061 TGTTTCGAACCTTTTGTGCAAGAAGAGTCGACAACCACACGCGAATATGGCGGTAGCGGCC 3120

Query 3150 TAGGTTTGACCATCGTTAAGAACCTAGTCGATATGTTAGAAAGGTGATGTTTCAGGTCCGCA 3209
          |||
Sbjct 3121 TAGGTTTGACCATCGTTAAGAACCTAGTCGATATGTTAGAAAGGTGATGTTTCAGGTCCGCA 3180

Query 3210 GTAGCAAGGGGGGGGGGACAACTTTGTTATAAACTTCCAGTAAAAGATCGTGAGCGTG 3269
          |||
Sbjct 3181 GTAGCAAGGGGGGGGGGACAACTTTGTTATAAACTTCCAGTAAAAGATCGTGAGCGTG 3240

Query 3270 TCTTAAGGCCTCTGGAGGTCAGTCAACGTATCAAGCCGGAAGCCTTGTGTTGATGAAAGTT 3329
          |||
Sbjct 3241 TCTTAAGGCCTCTGGAGGTCAGTCAACGTATCAAGCCGGAAGCCTTGTGTTGATGAAAGTT 3300

Query 3330 TAAAAGTGCTACTGGTGAAGATAACCATACCAATGCGTTTATCCTTCAGGCTTTCTGTGA 3389
          |||
Sbjct 3301 TAAAAGTGCTACTGGTGAAGATAACCATACCAATGCGTTTATCCTTCAGGCTTTCTGTGA 3360

Query 3390 AGAAGTATAAAATGCAGGTGGATTGGGCGAAAGATGGGCTGGACGCGATGGAGCTCCTTT 3449
          |||
Sbjct 3361 AGAAGTATAAAATGCAGGTGGATTGGGCGAAAGATGGGCTGGACGCGATGGAGCTCCTTT 3420

Query 3450 CTGATACCACCTACGATCTGATCCTCATGGATAACCAATTACCCACCTTGGTGGTATTG 3509
          |||
Sbjct 3421 CTGATACCACCTACGATCTGATCCTCATGGATAACCAATTACCCACCTTGGTGGTATTG 3480

Query 3510 AGACCACGCACGAGATTGCCAGAAGTGGAGGCTTGGAAACGCCAATTTACGCGGTACAG 3569
          |||
Sbjct 3481 AGACCACGCACGAGATTGCCAGAAGTGGAGGCTTGGAAACGCCAATTTACGCGGTACAG 3540

Query 3570 CAGACACCGCGAAAGAAACCAGTGATGCGTTTATGGCGGAGGTGCAAACCTATGTCATGC 3629
          |||
Sbjct 3541 CAGACACCGCGAAAGAAACCAGTGATGCGTTTATGGCGGAGGTGCAAACCTATGTCATGC 3600

Query 3630 TGAAGCCAATTAAGAGAAATGCGTTTACATGAGGCGTTTGTGCGATTTCAAACAACGTTTCT 3689
          |||
Sbjct 3601 TGAAGCCAATTAAGAGAAATGCGTTTACATGAGGCGTTTGTGCGATTTCAAACAACGTTTCT 3660

Query 3690 TGGTAGAAAGAACCTAACGGTTTAAATGGCAGTGATAAGTTAGGGGCTGAAGTTAAATAAT 3749
          |||
Sbjct 3661 TGGTAGAAAGAACCTAACGGTTTAAATGGCAGTGATAAGTTAGGGGCTGAAGTTAAATAAT 3720

Query 3750 AAAAGTAAAGAAGGAGCGTAATGCACTAATGCCGTTCACTTAAGGTGATCGGCATTGTT 3809
          |||
Sbjct 3721 AAAAGTAAAGAAGGAGCGTAATGCACTAATGCCGTTCACTTAAGGTGATCGGCATTGTT 3780

Query 3810 TTTTCTAGGTATCGG 3825
          |||
Sbjct 3781 TTTTCTAGGTATCGG 3796
    
```

(b)

```

Query 1127 MTTTRSNIKKRRSLATLITKIIILVLAPIILGIFIQSYFFSKQIIWQEVDRTKQQTSAI 1306
          MTTTRSNIKKRRSLATLITKIIILVLAPIILGIFIQSYFFSKQIIWQEVDRTKQQTSAI
Sbjct 1 MTTTRSNIKKRRSLATLITKIIILVLAPIILGIFIQSYFFSKQIIWQEVDRTKQQTSAI 60

Query 1307 HNIFDSHFAAIQIHHSNSKSEVIRDFYTDRTDVLNFFFLSIDQSDPSHTPEFRFLTDH 1486
          HNIFDSHFAAIQIHHSNSKSEVIRDFYTDRTDVLNFFFLSIDQSDPSHTPEFRFLTDH
Sbjct 61 HNIFDSHFAAIQIHHSNSKSEVIRDFYTDRTDVLNFFFLSIDQSDPSHTPEFRFLTDH 120

Query 1487 KGIIWDDGNAHFYGVNDLILDSLNRVFSFNWYYINVMTSIGSRHMLVRRVPILD PSTG 1666
          KGIIWDDGNAHFYGVNDLILDSLNRVFSFNWYYINVMTSIGSRHMLVRRVPILD PSTG
Sbjct 121 KGIIWDDGNAHFYGVNDLILDSLNRVFSFNWYYINVMTSIGSRHMLVRRVPILD PSTG 180
    
```

Jeremy Kubik

Query	1667	EVLGFSFNNAVVLDDNNFALMEKLLKSESNDVNVVLLVANSVPLANSLIGDEPYNVADVLQRKS	1846
Sbjct	181	EVLGFSFNNAVVLDDNNFALMEKLLKSESNDVNVVLLVANSVPLANSLIGDEPYNVADVLQRKS	240
Query	1847	SDKRLDKLLVIETPIVVNAVTTTELCLLTQDNQSVVTLQIQHILAMLASIIIGMIMIALMS	2026
Sbjct	241	SDKRLDKLLVIETPIVVNAVTTTELCLLTQDNQSVVTLQIQHILAMLASIIIGMIMIALMS	300
Query	2027	REWIESKVSQALESLSYTRSAREEKGFERFGGSDIEEFDHIGSTLESTFEELEAQKKS	2206
Sbjct	301	REWIESKVSQALESLSYTRSAREEKGFERFGGSDIEEFDHIGSTLESTFEELEAQKKS	360
Query	2207	RDLFNFALSPIMVWSEESVLIQMNPAARKELVIEDDHEIMHPVFQGFKEKLTPLHKMAAQ	2386
Sbjct	361	RDLFNFALSPIMVWSEESVLIQMNPAARKELVIEDDHEIMHPVFQGFKEKLTPLHKMAAQ	420
Query	2387	GATLTGVNVPIGNKIYRWNLSPPIRVGDGDISGIIVQGGDITTLIEAEKQSNIRAREAEKSA	2566
Sbjct	421	GATLTGVNVPIGNKIYRWNLSPPIRVGDGDISGIIVQGGDITTLIEAEKQSNIRAREAEKSA	480
Query	2567	QARADFLAKMSHEIRTPINGILGVAQLLKDSVDTQEQQNKQIDVLCHSGEHLAVLNDILD	2746
Sbjct	481	QARADFLAKMSHEIRTPINGILGVAQLLKDSVDTQEQQNKQIDVLCHSGEHLAVLNDILD	540
Query	2747	FSKIEQGGKFNQKHPFSFTDTMRTLENIYRPICTNKGVELVIENELDPNVEIFTDQVRLN	2926
Sbjct	541	FSKIEQGGKFNQKHPFSFTDTMRTLENIYRPICTNKGVELVIENELDPNVEIFTDQVRLN	600
Query	2927	QILFNLVSNVAVKFTPIGSIRLHAELEQFYGAENSVLVVELTDTTGIGIESDKLDQMFEPFV	3106
Sbjct	601	QILFNLVSNVAVKFTPIGSIRLHAELEQFYGAENSVLVVELTDTTGIGIESDKLDQMFEPFV	660
Query	3107	QEESTTTREYGGSGLGLTIVKNLVDMLEGDVQVRSKGGGTTFVITLQVDRERVLRPLE	3286
Sbjct	661	QEESTTTREYGGSGLGLTIVKNLVDMLEGDVQVRSKGGGTTFVITLQVDRERVLRPLE	720
Query	3287	VSQRIKPEALFDES LKVLLEDNHTNAFILQAFCKKYMVDWAKDGLDAMELLS DTTYD	3466
Sbjct	721	VSQRIKPEALFDES LKVLLEDNHTNAFILQAFCKKYMVDWAKDGLDAMELLS DTTYD	780
Query	3467	LILMDNQLPHLGGIETTHEIRQNLRLGTPIYACTADTAKETS DAFMAAGANYVMLKPIKE	3646
Sbjct	781	LILMDNQLPHLGGIETTHEIRQNLRLGTPIYACTADTAKETS DAFMAAGANYVMLKPIKE	840
Query	3647	NALHEAFVDFKQRFVVERT	3703
Sbjct	841	NALHEAFVDFKQRFVVERT	859

**Figure 7. Nucleotide and amino acid sequence alignment of *luxPQ* and  $\Delta$ *luxPQ*.** (a)


Nucleotide alignment of  $\Delta$ *luxPQ* (Query) and *luxPQ* (Subject). The coding sequence for *luxP* on the query sequence is from nucleotide 30 to 1127, whereas nucleotides 1126 to 3706 code for  $\Delta$ *luxQ*. Three silent mutations were introduced to *luxPQ* [*Vibrio harveyi* ATCC BAA-1116] by QuikChange XL Site-Directed Mutagenesis in order to remove BBK sites, and thus generate  $\Delta$ *luxPQ*. This was then sequenced and aligned (BLAST) with *luxPQ* to verify the removal of these sites. Nucleotides 599 ( $\Delta$ *luxP*) and 1465

Jeremy Kubik

( $\Delta luxQ$ ) were mutated from 'A' to 'G' resulting in the loss of the *EcoRI* site, and nucleotide 1618 ( $\Delta luxQ$ ) was mutated from 'T' to 'G' to remove the *XbaI* restriction site. The restriction sites are highlighted in green on the *luxPQ* sequence (Subject) whereas the mutated sites are highlighted in yellow on the  $\Delta luxPQ$  sequence (Query). Mutagenic primers (black arrows) are also depicted. Alignment was 99% (3793/3796) with no gaps.

(b) Amino acid alignment of *luxPQ* (Subject) and  $\Delta luxPQ$  (Query). The sequences align 100%, with no gaps, revealing that the mutations present in  $\Delta luxPQ$  were silent and thus did not affect the amino acid sequence.


Jeremy Kubik



**Figure 8.** BBK PCR amplification of  $\Delta luxPQ$  from pCR-BLUNT-II-TOPO with *LuxPQ*-RS-F and *LuxPQ*-RS-R primers run on a 0.8% agarose gel (90V). GeneRuler 1kb DNA Ladder Plus (Fermentas, ON) was loaded into wells 1 and 7, PCR products with the same  $\Delta luxPQ$  template in TOPO was loaded into wells 2-5 and the negative control (water) in well 6. BBK PCR amplification of  $\Delta luxPQ$  reveals expected band sizes of just under 4.0kb.




Jeremy Kubik



**Figure 9. Colony PCR to verify  $\Delta luxPQ$  plasmid switch from psB1AK3 to psB1AC3 using LuxPQ-F/R and BBK-CP-F/R primers on a 0.8% agarose gel (90V). 5 $\mu$ L of GeneRuler 1kb DNA Ladder Plus (Fermentas, ON) were loaded into wells 1 and 18. Six colonies were screened with both sets of primers.  $\Delta luxPQ$  in psB1AK3 was used as the positive control. This gel confirms the presence of  $\Delta luxPQ$  in psB1AC3 for colonies 1, 2, 3, 4 and 5 because of the desired band size of 3.9-4.0kb.**


Jeremy Kubik



**Figure 10.** Colony PCR to verify presence of signalling circuit ( $\Delta luxPQ$ -B0015-R0040-*LuxOU*-B0015) in psB1AC3 using BBK-CP-F/R and LuxPQ-F/LuxOU-R primers on a 0.8% agarose gel (90V). Seven colonies were screened with two set of primers (lanes 2-8, 11-17) and the signalling circuit in psB1AK3 was used as a positive control. Colony 3 was the only colony with the desired band size of around 6.1kb.

Jeremy Kubik

(a)



(b) Sequence from primer 1 (BBK-CP-F)

```

AATAGGCGTATCACGAGGCAGAATTCAGATAAAAAAATCCTTAGCTTTCGCTAAGGATGATTTCTGGAATTCGCGGC
CGCTTCTAGAAATGCTCGATAAAAACTAAAAGAGCAATAGATGAAGAAAGCGTTACTATTTTCCCTGATTTCTATGGTCG
GTTTTTCTCCAGCGTCTCAAGCAACACAAGTTTTGAATGGGTACTGGGGTTATCAAGAGTTTTTGGACGAGTTTCCCGA
GCAACGAAATCTGACCAATGCTTTATCAGAAGCAGTACGAGCACAGCCGGTCCCACTGTCTAAACCACACAACGCCCG
ATTAATAATATCAGTGGTTTACCCAGGACAGCAAGTTTCAGATTACTGGGTAAGAAATATTGCATCATTCGAAAAACGTT
TGTATAAGTTGAATATTAAC TACCAACTGAACCAAGTGT TACTCGTCCAATGCTGATATCAAGCAACAAAGCTTGTC
ATTAATGGAAGCGCTCAAGAGCAAATCGGATTACTTGTATTTTACGCTTGATACGACAAGACACCGTAAATTTGTTGAG
CAGTTTTGGACTCAACGAACACCAAATTGATCTTGC AAAATATCACTACACCAGTCCGTGAGTGGGACAAACATCAAC
CGTTTTTATATGTCGGATTTGACCACGCAGAAGGCAGTCTGTAATTAGCAACAGAGTTCGGAAAGTTCTTCCAAAAACA
CACATATTACAGTGTGCTCTACTTTTCTGAAGTTATATTAGCGATGTGAGAGGTGATACTTTTATTCACCAAGTAAAC
CGTGATAATAACTTTGAGCTACAATCAGCGTATTACACGAAGGCCAACCAAGCAATCCGGCTATGATGCTGCGAAAGCGA
GTTTAGCAAACATCCAGATGTTGATTTTATCTATGCATGTTGACCCGACGTAGCATTAGGTGCAGTAGACGCACTGGCT
GAGTTGG
    
```

(c) Sequence from primer 2 (R0040-R)

```

CTATCCTGATAGGGA CTCTAGTATATAAAACGCAGAAAGGCCACCCGAAGGTGAGCCAGTGTGACTCTAGTAGAGAGCG
TTCACCGACAAACAACAGATAAAAACGAAAGGCCAGTCTTTTCGACTGAGCCTTTTCGTTTTATTTGATGCCTGGCTCTAG
TCCGATACCCTAGAAAAACAATGCCGATCACCTTAAGTGAACGGCATTAGTGCATTACGCTCCCTTCTTTACTTTTAT
TATTTAACTTCAGCCCTAACTTATCACTGCCATTAACCGTTAGGTTCTTTCTACCAAGAAACGTTGTTTGAATCGA
CAAACGCCCTCATGTAACGCATTCTCTTAATTGGCTTCAGCATGACATAGTTTGCACCTGCCGCCATAAACGCATCACT
GGTTCTTTTCGGGTGTCTGCTGTACACGCATAAATTGGCGTTCCAAGCCTCAAGTCTGGCGAATCTCGTGCCTGGTC
CAATACCACCAAGGTGGGGTAATTGGTTATCCATGAGGATCAGATCGTAGGTGGTATCAGAAAGGAGCTCCATCGCGT
CCAGCCCATCTTTCGCCAATCCACTGCATTTTATACTTCTTACAGAAAGCCTGAAGGATAAACGCATTGGTATGGTT
ATCTTCCACCGTAGCACTTTTAACTTTCATCAACAAGGCTTCCGGCTTGATACGTTGACTGACCTCCAGAGGCCTT
AAGACACGCTCACGATCTTTTACTGGAAGTGTATAACAAATGTTGTC CCCCCCTTGTACTGCGGACCTGAACAT
CACCTTCTAACATATCGACTAGGTTCTTAACGATGGTCAAACCTAGGCCGCTACCGCCATATTCGCGTGTGGTTGTGCA
CTCTCTTGCACAAAAGGTTTCAACATTTGGTTCGAGCTTATCGCTTTCAATGCCGATGCCAGTATCAGTCAGTCCACA
ACTAACACGCTGTTCTCCGCACCATAGAATTGTTCAAGTTCTGCGTGCAG
    
```

(d) Sequence from primer 3 (BBK-CP-R)

```

CCTTGCCCTTTTTTTCGCGGA CTGCAGCGGCGCTACTAGTATAATAACGCAGAAAGGCCACCCGAAGGTGAGCCAGTG
TGACTCTAGTAGAGAGCGTTCACCGACAAACAACAGATAAAAACGAAAGGCCAGTCTTTTCGACTGAGCCTTTTCGTTTTA
TTTGATGCCTGGCTCTAGTCCCATTTCAAATCTCCTCATGGTTGGAGACTTGATCTTATTCTTCGCGCTAGGCCGATTAG
AATGCGGGTTTTATGGAGCGCTTACTGTCTAACTAGACGAAAAGCATTGAGAAAGCGGCTTCGATTTCGGAGCAAACCTCC
CAAACA AAAAAGCCCTTCCACACCGGAAGGGCTTTGTGTTTTTACGTTGCGCTTAATGTCTTGCTCGAAACGTTAGTT
TGTCCAAGAACGGTAGGCGTCACGAGTGATATGAAGTAAAGCGAGCATTTTCGCTCGTCTCCATCCCCTGCTCTTGCAAT
TGATTGCTTTTTGCTTTCTTGTGATGGCAATCGCTCGTTACACAATCGATCTGCGCAAAGCTGGCAGCACTACTTT
TCAGTGGTGGCTGATCTCTTTTAAATACAACAGCTGCTCTGAGCCCTGAAGTTCAGTTAAAGTGCCAATGTAGGAGTC
CATTTCCCAAGAAAAATATCAAGCAAAACAGGAACATTATCGTACCAATTTCCGCAGACAGTCTTCAATTTTTTGC
TGATTTAATACGTCGATTCATACGTTTTGTTTTTTCGCTTATTCGCTTATTCGAACTTGCAACTTGCGATAAATCGTTGA
TGGACTAACATCCAAATAGCCAGCAGCGCTGGAATGTTG
    
```


**Figure 11. Schematic of annealing regions for sequencing primers and DNA**

**sequences for signalling circuit in psB1AC3.** (a) This schematic diagram depicts the annealing regions of the primers (black arrows) used for sequencing of the signalling


Jeremy Kubik

circuit in psB1AC3, shown as 'AC'. Black arrows numbered 1, 2 and 3 represent primers BBK-CP-F, R0040-R and BBK-CP-R respectively. (b) Sequencing results from primer 1 (BBK-CP-F). Colour scheme: grey – BBK vector backbone, green – BBK prefix restriction sites, pink –  $\Delta luxPQ$ . (c) Sequencing results from primer 2 (R0040-R). Colour scheme: cyan – R0040 promoter, red – B0015 terminator, pink –  $\Delta luxPQ$ . The pink  $\Delta luxPQ$  sequence shown in (b) and (c) corresponds to the  $\Delta luxPQ$  that was previously sequenced and aligned with *luxPQ* (Figure 7a). (d) Sequencing results from primer 3 (BBK-CP-R). Colour scheme: grey – BBK vector backbone, green – BBK suffix restriction sites, red – B0015 terminator, orange – *luxOU*.

Jeremy Kubik




**Figure 12.** Plasmid PCR to verify presence of signalling circuit in pCS26 by using the pCS26-S-F primer with LuxPQ-R and LuxOU-R primers. Seven colonies were screened with the two sets of primers, with no positive control. The first set of primers verifies the presence of  $\Delta luxPQ$ , whereas the second primer set verifies both (1) the presence of *luxOU* and (2) if a construct of the size of the signalling circuit is present. Colonies 3 and 8 revealed expected sizes for each pair of primers: 4.0kb and ~6.1kb.



**Figure 13. Sequencing primers and DNA sequences for signalling circuit in pCS26.**

(a) This schematic diagram depicts the annealing regions of the primers (black arrows) used for sequencing of the signalling circuit. Arrows numbered 1 and 2 represent pCS26-S-F and LuxOU-R respectively. (b) Sequencing results from primer 1 (pCS26-S-F). Colour scheme: grey – pCS26 vector backbone, blue – *NotI* restriction site, bright green – *XbaI* restriction site, pink – *luxP*. (c) Sequencing results from primer 2 (LuxOU-R). Colour scheme: orange – *luxOU*.



**Figure 14. Flow chart of construction and use of mutant, reporter, response and signalling circuits.** Each circuit is schematically depicted above or below its description in the blue/green boxes. The mutant circuits will be tested with KT1144 cells and then used to test the reporter and response circuits. The reporter will then be used to test the signalling circuit. The signalling and response circuits will then be coupled to reach the end goal of the AI-2 signalling system in *E. coli*. Boxes in light green depict what has been described in this paper. Accomplished to date include construction of mutant and reporter circuits and partial construction of the response circuit. The mutants are currently being tested.

## References

- <sup>1</sup> Waters, C.M. & Bassler, B.L.. Quorum sensing: cell-to-cell communication in bacteria. *Annu. Rev. Cell Dev. Biol.* **21**, 319-346 (2005).
- <sup>2</sup> Hardman, A.M., Stewart, G.S. & Williams P. Quorum sensing and the cell-cell communication dependent regulation of gene expression in pathogenic and non-pathogenic bacteria. *Antonie van Leeuwenhoek.* **74**, 199-210 (1998).
- <sup>3</sup> Nealson, K. H., Platt, T. & Hastings, W. Cellular Control of the synthesis and activity of the bacterial bioluminescent system. *J. Bacteriol.* **104**, 313-322 (1970).
- <sup>4</sup> Eberhard, A., Burlingame, A.L., Kenyon, G.L., Nealson, K.H. & Oppenheimer, N.J. Structural identification of autoinducer of *Photobacterium fischeri* luciferase. *Biochemistry.* **20**, 2444-2449 (1981).
- <sup>5</sup> Sun, J., Daniel, R., Wagner-Dobler I. & Zeng, A.P. Is autoinducer-2 a universal signal for interspecies communication: a comparative genomic and phylogenetic analysis of the synthesis and signal transduction pathways, *BMC Evol. Biol.* **4**, 36 (2004).
- <sup>6</sup> Bassler, B.L., Wright, M., Silverman, M.R. Multiple signaling systems controlling expression of luminescence in *Vibrio harveyi*: sequence and function of genes encoding a second sensory pathway. *Mol. Microbiol.* **13**, 273-286 (1994).
- <sup>7</sup> Lilley, B.N. & Bassler, B.L. Regulation of quorum sensing in *Vibrio harveyi* by LuxO and sigma-54. *Mol. Microbiol.* **36**, 940-54 (2000).
- <sup>8</sup> Lenz, D.H., Mok, K.C., Lilley, B.N., Kulkarni, R.V., Wingreen, N.S. & Bassler, B.L. The small RNA chaperone Hfq and multiple small RNAs control quorum sensing in *Vibrio harveyi* and *Vibrio cholerae*. *Cell* **118**, 69-82 (2004)
- <sup>9</sup> Swartzman, E., Silverman, M. & Meighen, E.A. The *luxR* gene product of *Vibrio harveyi* is a transcriptional activator of the *lux* promoter. *J. Bacteriol.* **174**, 7490-7493 (1992)
- <sup>10</sup> Kaplan, H.B. & Greenberg, E.P. Diffusion of autoinducer is involved in regulation of the *Vibrio fischeri* luminescence system. *J. Bacteriol.* **163**, 1210-1214 (1985).
- <sup>11</sup> Stevens, A.M., Dolan, K.M., & Greenberg, E.P. Synergistic binding of the *Vibrio fischeri* LuxR transcriptional activator domain and RNA polymerase to the *lux* promoter region. *Proc. Natl. Acad. Sci. USA* **91**, 12619-12623 (1994)
- <sup>12</sup> Lyon G.J. & Muir, T.W. Chemical Signaling among Bacteria and Its Inhibition. *Chem. Biol.* **10**, 1007-1021 (2003)
- <sup>13</sup> Sambrook, J.A & Russell, D.W. *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbor Laboratory Press. (2001).
- <sup>14</sup> Feng, J. *luxOU* and AI-2: Regulating the response in Biobrick format. Unpublished (2009). Available at <http://2009.igem.org/Team:Calgary>
- <sup>15</sup> Moinul, P. Facilitating Quorum Quenching with Autoinducer Inactivation Enzyme. Unpublished (2009). Available at <http://2009.igem.org/Team:Calgary>
- <sup>16</sup> Davies, D. G., M. R. Parsek, J. P. Pearson, B. H. Iglewski, J. W. Costerton, & Greenberg, E.P. The involvement of cell-to-cell signals in the development of a bacterial biofilm. *Science* **280**, 295-298 (1998)
- <sup>17</sup> Kaplan, J.B., Raganath, C., Ramasubbu, N. & Fine, D.H. Detachment of *Actinobacillus actinomycetemcomitans* biofilm cells by an endogenous beta-hexosaminidase activity, *J. Bacteriol.* **185**, 4693-4698 (2003).
- <sup>18</sup> Chen, X., Schauder, S., Potier, N., Van Dorsselaer, A., Pelczer, I, Bassler, B.L., & Hughson, F.M. Structural identification of a bacterial quorum-sensing signal containing boron. *Nature* **415**, 545-549 (2002).
- <sup>19</sup> Andresson, D.I. Persistence of antibiotic resistance bacteria. *Current Opinion in Microbiology.* **6**, 452-456 (2003).